gmp
gmp

Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothExpert and Agile CDMO Partner for tailor-made solutions.

            Contact the Supplier

            Lead Product(s): Imatinib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aerami

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 08, 2020

            Details:

            Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium Nitrite

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: JanOne

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 06, 2020

            Details:

            CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INS-3001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MAT9001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: BTIG

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 09, 2020

            Details:

            Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology